Skip to main content
. Author manuscript; available in PMC: 2015 Jan 8.
Published in final edited form as: J Endocrinol Diabetes Obes. 2014 Oct;2(4):1057.

Table 2.

Incidence of ≥ 0.5 HbA1c decrease from baseline after one, three and six months of treatment, ITT population.

D-tagatose 2.5g D-tagatose 5.0g D-tagatose 7.5g
Treatment
Duration
N = 51
n (%)
N = 46
n (%)
N = 47
n (%)
One Month 8 (15.38%) 9 (19.57%) 4 (8.51%)
Three Months 11 (21.15%) 8 (17.39%) 5 (10.64%)
Six Months 10 (19.23%) 7 (15.22%) 12 (25.53%)

N = denominator for all percentages